Whalesbook
Eli Lilly has become the first drugmaker to reach a $1 trillion market value, driven by the booming demand for its weight-loss drugs like Mounjaro and Zepbound. This achievement places it among tech giants and highlights obesity treatment as a major, lucrative segment in healthcare. Analysts predict the market could reach $150 billion by 2030, with Lilly poised for further growth with upcoming drugs like orforglipron.